VLDLR and breast carcinoma: According to a recent study, hsa-miR-1262 acts as an antitumor miRNA that can modulate the expression levels of the low-density lipoprotein receptor (LDLR)-related protein 8 (LRP8), affecting cellular processes such as proliferation, invasion, and migration of breast cancer cells [82].